BofA raised the firm’s price target on Oculis (OCS) to $44 from $43 and keeps a Buy rating on the shares following the company’s Q1 update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis reports Q1 EPS (49c), consensus (41c)
- Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results
- Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes
- Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing
- Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session